RxDoctor Payments Data

James Barton, MD

Internal Medicine · Jasper, ALNPI 1275567182

Payments from drug & device makers

$280in general payments, 2019–2025

Across 17 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$102
  • Pfizer$71
  • GSK$54
  • AbbVie$20
  • Octapharma USA, Inc.$17
  • AstraZeneca$17

What the payments were for

  • Food & beverage$280100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)7$102
Pfizer3$71
GSK4$54
AbbVie1$20
Octapharma USA, Inc.1$17
AstraZeneca1$17

How this compares

$280 in reported general payments places this provider in the 40th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$197,051
Medicare patients
234
Services billed
3,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$185,737
OzempicSemaglutide131$169,502
JardianceEmpagliflozin109$100,283
TrulicityDulaglutide77$91,386
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$79,391
OtezlaApremilast12$68,348
LinzessLinaclotide67$60,730
MounjaroTirzepatide29$51,756
XareltoRivaroxaban55$51,581
JanuviaSitagliptin Phosphate46$45,721
JanumetSitagliptin Phos/Metformin Hcl36$37,938
FarxigaDapagliflozin Propanediol33$31,624
EntrestoSacubitril/Valsartan23$28,128
Victoza 3-PakLiraglutide32$28,013
MyrbetriqMirabegron28$24,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$185,737251 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$54$110,454123 claims
AbbVieLinzess$20$60,73067 claims
Johnson & JohnsonXarelto$102$51,58155 claims
AstraZenecaFarxiga$17$31,62433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Jasper

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →